IMIván Maldonado

Iván Maldonado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iván Maldonado has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Gustavo Puras

    NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, Vitoria-Gasteiz 01006, Spain.; Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz 01009, Spain.; Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, Madrid 28029, Spain.

    3 shared publications
  • Idoia Gallego

    NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain

    3 shared publications
  • José Luis Pedraz

    NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain

    3 shared publications
  • Cristina Soto-Sánchez

    Bioengineering Institute, University Miguel Hernández, Elche, Spain

    2 shared publications
  • Desirée González

    Biomedical Neuroengineering, Institute of Bioengineering (IB), University Miguel Hernández (UMH), 03020 Elche, Spain

    2 shared publications
  • Eduardo Fernández

    Bioengineering Institute, University Miguel Hernández, Elche, Spain

    2 shared publications

Latest Publications

  • Open Access

    Evaluation of Lipid Nanoparticles as Vehicles for Optogenetic Delivery in Primary Cortical Neurons

    by José David Celdrán, Lawrence Humphreys, Maria Jose Verdú, Desirée González, Cristina Soto-Sánchez, Gema Martínez-Navarrete, Lucía Enríquez, Iván Maldonado, Idoia Gallego, Mohamed Mashal, et al.

    Background: Gene therapy has experienced significant development since its origin decades ago, resulting in therapies for a wide range of diseases. In this context, optogenetics has emerged as a promising therapy for treating diseases in a precise spatiotemporal way using light. Transporting optogenetic genes to target cells is achieved using viral vectors, specifically AAV vectors. These vectors present limited cargo capacity, and a large percentage of the population carries AAV neutralizing antibodies. In this regard, lipid nanoparticles can overcome some of the previously mentioned problems of AAV vectors, making them prime candidates for optogenetic delivery. Methods: In this study, we evaluated their suitability for the delivery of the ChrimsonR plasmid in neurons in vitro. Results: In rat cortical neurons, in most of the concentrations tested, there was no reduction in several neuron morphological parameters that we measured when compared to another non-viral nanoparticle called lipofectamine. Transfection efficiency was significantly higher compared to lipofectamine in almost all treatments. Further in vitro analysis showed that electrophysiological parameters were altered, with reduced signal amplitudes; however, cell viability assays showed no decline in cell viability. Conclusions: These results demonstrate that lipid nanoparticles represent a promising non-viral platform for optogenetic delivery, though formulation optimization is required to achieve full functional efficacy.

  • Open Access

    Comparative analysis of lipid-peptide nanoparticles prepared via microfluidics, reverse phase evaporation, and ouzo techniques for efficient plasmid DNA delivery

    by Mohamed Mashal, Noha Attia, Iván Maldonado, Lucía Enríquez Rodríguez, Idoia Gallego, Gustavo Puras, José Luis Pedraz


  • Open Access

    Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects

    by José David Celdrán, Lawrence Humphreys, Desirée González, Cristina Soto-Sánchez, Gema Martínez-Navarrete, Iván Maldonado, Idoia Gallego, Ilia Villate-Beitia, Myriam Sainz-Ramos, Gustavo Puras, et al.

    Gene therapy and optogenetics are becoming promising tools for treating several nervous system pathologies. Currently, most of these approaches use viral vectors to transport the genetic material inside the cells, but viruses present some potential risks, such as marked immunogenicity, insertional mutagenesis, and limited insert gene size. In this framework, non-viral nanoparticles, such as niosomes, are emerging as possible alternative tools to deliver genetic material, avoiding the aforementioned problems. To determine their suitability as vectors for optogenetic therapies in this work, we tested three different niosome formulations combined with three optogenetic plasmids in rat cortical neurons in vitro. All niosomes tested successfully expressed optogenetic channels, which were dependent on the ratio of niosome to plasmid, with higher concentrations yielding higher expression rates. However, we found changes in the dendritic morphology and electrophysiological properties of transfected cells, especially when we used higher concentrations of niosomes. Our results highlight the potential use of niosomes for optogenetic applications and suggest that special care must be taken to achieve an optimal balance of niosomes and nucleic acids to achieve the therapeutic effects envisioned by these technologies.


  • Bektore ez-biral lipidikoak garatzeko erabiltzen diren teknikak eta hauen garrantzia etorkizunerako

    by Jose Luis Pedraz Muñoz, Noha Attia, Mohamed Mashal, Idoia Gallego Garrido, Lucia Enriquez Rodriguez, Gustavo Puras Ochoa, Jon Zarate Sesma, Ivan Maldonado Pérez

    Bektore ez-biral lipidikoak garatzeko erabiltzen diren teknikak eta hauen garrantzia etorkizunerako produkzioaren informazio-fitxa